Targeting EGFR in Triple-Negative Breast Cancer

[tousled1]

Breast tumors which are neither positive for ER, PR, or HER2 are colloquially referred to as triple-negative (http://www.curetoday.com/cureXtra/currentissue/archive/jan07/index.html), due to their lack of either hormonal or growth factor related marker expression. These tumors are not responsive to either hormonal therapy or HER2-targeted agents, and thus chemotherapy is often the only effective treatment. Interestingly, expression of the HER2-related gene, HER1 — more commonly known as epidermal growth factor receptor (EGFR) — has been seen in expression profiles of triple-negative tumors, and thus EGFR-targeted therapy may be efficacious in this setting

To read full article:

http://www.curetoday.com/sabcs2007/sat/brief.php